SCHEMBL4285893

SCHEMBL4285893

O=C(O)N1CCN(C(c2ccccc2)(c2ccccc2)c2ccccc2)[C@H](CSc2cccc(F)c2)C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.38
GRM2 Q14416 1/20 0.36
GRM3 Q14832 1/20 0.36
CTSK P43235 1/20 0.36
MAPK1 P28482 1/20 0.35
SMN1; SMN2 Q16637 3/20 0.34
NPC1 O15118 1/20 0.34
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.34
TSHR P16473 1/20 0.34
RAB9A P51151 1/20 0.34
SLC6A9 P48067 3/20 0.34
PTGER1 P34995 1/20 0.34
PTGFR P43088 1/20 0.34
MEN1 O00255 1/20 0.33
POLB P06746 1/20 0.33
KMT2A Q03164 1/20 0.33
FAAH O00519 1/20 0.33
MDM4 O15151 1/20 0.33
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4288482 0.79 USP2 (0.41) GAAMAPK1LMNATSHRMEN1
SCHEMBL4296583 0.76 TACR1 (0.37) GAAMAPK1LMNATSHRMEN1
SCHEMBL17942512 0.73 CTSK (0.44) GRM2GRM3CTSKSMN1; SMN2NPC1
SCHEMBL4750154 0.72 SMN1; SMN2 (0.41) MAPK1SMN1; SMN2LMNATSHRMEN1
SCHEMBL4290185 0.68 TEAD1 (0.35) SMN1; SMN2LMNAMEN1KMT2A
SCHEMBL4284001 0.67 CA1 (0.47) SMN1; SMN2
SCHEMBL17601 0.67 GCKR (0.45)
SCHEMBL20141040 0.65 RORC (0.43) SMN1; SMN2NPC1LMNAMAPTTSHR
SCHEMBL4290686 0.63 ENPP2 (0.43)
SCHEMBL17942453 0.62 GPR119 (0.51) MEN1KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227560-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 US disclosed
US-20090156612-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed
WO-2008139941-A1 SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156612-A1 Substituted imidazole compound and use thereof REN, ACE, AGT GAA 1381/4885GRM2 4145/4885GRM3 3661/4885
US-20090227560-A1 Substituted imidazole compound and use thereof REN, ACE, AGT GAA 1381/4885GRM2 4145/4885GRM3 3661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.